

Übersicht der bestätigten Publikationen 2013-2015

Prof. Dr. med. Christoph Thomssen

Journalbeitrag

1. Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S (2013) Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. *JOURNAL OF CLINICAL ONCOLOGY*, 31: 2532-9
2. Harbeck N, Scharl A, Thomssen C, Müller V (2013) AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. *BREAST CARE*, 8: 181-5
3. Harbeck N, Thomssen C, Gnant M (2013) St. Gallen 2013: brief preliminary summary of the consensus discussion. *BREAST CARE*, 8: 102-9
4. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CGJ, Lisboa BW, Lux MP, Beck T, Hasmmüller S, Kiechle M, Jänicke F, Thomssen C, Chemo-N 0 Study Group (2013) Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. *EUROPEAN JOURNAL OF CANCER*, 49: 1825-35
5. Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N (2013) Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. *BREAST CANCER RESEARCH AND TREATMENT*, 138: 839-50
6. Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, European School of Oncology-Metastatic Breast Cancer Task Force (2013) International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. *BREAST*, 22: 203-10
7. Lück HJ, Du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G (2013) Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. *BREAST CANCER RESEARCH AND TREATMENT*, 139: 779-87
8. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M, AGO Breast Study Group (2013) Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. *JNCI-Journal of the National Cancer Institute*, 105: 1018-26
9. Scharl A, Thomssen C, Harbeck N, Müller V (2013) AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013. *BREAST CARE*, 8: 174-80
10. Thomssen C, Diel I, Gnant M, Goldmann-Posch U, Göschke C, Haidinger R, Janni W, Lin NU (2013) Follow-up after breast cancer diagnosis. *BREAST CARE*, 8: 457-60
11. Thomssen C, Harbeck N (2013) ABC2 Consensus Conference on Advanced Breast Cancer: Brief Summary of the Consensus Panel on Saturday November 9, 2013. *BREAST CARE*, 8: 455-6
12. Trocchi P, Holzhausen HJ, Böcker W, Schmidt-Pokrzywniak A, Ruschke K, Thomssen C, Löning T, Kluttig A, Stang A (2013) Influence of immunohistochemistry on the final diagnosis of breast biopsies. *HISTOPATHOLOGY*, 63: 817-25
13. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Dimpfl T, Eiermann W, Fehm T, Friese K, Jänicke F, Janni W, Jonat W, Kiechle M, Köhler U, Lück HJ, Maass N, Possinger K, Rody A, Scharl A, Schneeweiss A, Thomssen C, Wallwiener D, Welt A (2013) 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013). *BREAST CARE*, 8: 221-9

14. von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S (2013) German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. *JOURNAL OF CLINICAL ONCOLOGY*, 31: 3531-9
15. Aapro MS, De Laurentiis M, Mamounas E, Martin M, Rea D, Rouzier R, Smit V, Thomssen C (2014) 14p * adoption of multi-gene assays in hr +, her2- breast cancer (bc) patients in europe: results of the multidisciplinary application of genomics in clinical practice (magic) survey. *ANNALS OF ONCOLOGY*, 25 Suppl 1: i5-i6
16. Harbeck N, Marschner N, Untch M, Decker T, Hegewisch-Becker S, Jackisch C, Huober J, Lück HJ, von Minckwitz G, Scharl A, Schneeweiss A, Tesch H, Welt A, Wuerstlein R, Thomssen C (2014) Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. *BREAST CARE*, 9: 52-9
17. Kantelhardt EJ, Zerche P, Mathewos A, Trocchi P, Addissie A, Aynalem A, Wondemagegnehu T, Ersumo T, Reeler A, Yonas B, Tinsae M, Gemechu T, Jemal A, Thomssen C, Stang A, Bogale S (2014) Breast cancer survival in Ethiopia: a cohort study of 1,070 women. *INTERNATIONAL JOURNAL OF CANCER*, 135: 702-9
18. Kantelhardt EJ, Mathewos A, Aynalem A, Wondemagegnehu T, Jemal A, Vetter M, Knauf E, Reeler A, Bogale S, Thomssen C, Stang A, Gemechu T, Trocchi P, Yonas B (2014) The prevalence of estrogen receptor-negative breast cancer in Ethiopia. *BMC CANCER*, 14: 895
19. Kantelhardt EJ, Moelle U, Begoihn M, Addissie A, Trocchi P, Yonas B, Hezkiel P, Stang A, Thomssen C, Vordermark D, Gemechu T, Gebrehiwot Y, Wondemagegnehu T, Aynalem A, Mathewos A (2014) Cervical cancer in Ethiopia: survival of 1,059 patients who received oncologic therapy. *ONCOLOGIST*, 19: 727-34
20. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M, AGO Breast Study Group (2014) Response. *JNCI-Journal of the National Cancer Institute*, 106: djt452
21. Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C (2014) Cardiotoxicity and oncological treatments. *Deutsches Arzteblatt International*, 111: 161-8
22. Thomssen C, Harbeck N (2014) Cutting-edge therapy concepts - cure metastatic breast cancer? *BREAST CARE*, 9: 5-6
23. Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F, Thomssen C, Costa SD, Ignatov A (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. *ENDOCRINE-RELATED CANCER*, 22: 725-33
24. Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A (2015) Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. *BREAST CANCER RESEARCH AND TREATMENT*, 150: 279-88
25. Gnant M, Thomssen C, Harbeck N (2015) St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. *BREAST CARE*, 10: 124-30
26. Heil J, Kümmel S, Schaeffgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, Loibl S, Blohmer JU, von Minckwitz G (2015) Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. *BRITISH JOURNAL OF CANCER*, 113: 1565-70
27. Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M (2015) 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. *BREAST CARE*, 10: 211-9
28. Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonnaya A, Stensheim H, Thomssen C, van Calsteren K, Poortmans P, Berveiller P, Markert UR, Amant F (2015) Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. *JAMA ONCOL*, 1: 1145-53
29. Untch M, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Jackisch C, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Loibl S (2015) Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International

Breast Cancer Conference 2015 (Vienna 2015). GEBURTSHILFE UND
FRAUENHEILKUNDE, 75: 556-565

30. von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, German Breast Group Investigators (2015) A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). *CANCER*, 121: 3639-48